Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.78 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.62 |
| ▸ | KLK1 | P06870 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | PLK1 | P53350 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27612936 | 0.90 | ALDH1A1 (0.65) | ALDH1A1L3MBTL1KMT2AKLKB1KLK1 | |
| SCHEMBL5378962 | 0.87 | KMT2A (0.64) | ALDH1A1L3MBTL1KMT2AKLKB1KLK1 | |
| SCHEMBL974635 | 0.85 | KLKB1 (0.67) | ALDH1A1L3MBTL1KMT2AKLKB1KLK1 | |
| SCHEMBL16246844 | 0.85 | ALDH1A1 (0.62) | ALDH1A1L3MBTL1KMT2AKLKB1KLK1 | |
| SCHEMBL5385778 | 0.85 | KMT2A (0.70) | ALDH1A1L3MBTL1KMT2AKLKB1KLK1 | |
| SCHEMBL20027639 | 0.83 | ALDH1A1 (0.56) | ALDH1A1L3MBTL1KMT2AKLKB1KLK1 | |
| SCHEMBL3493198 | 0.82 | KMT2A (0.58) | ALDH1A1L3MBTL1KMT2AKLKB1KLK1 | |
| SCHEMBL6683912 | 0.80 | ALDH1A1 (0.65) | ALDH1A1L3MBTL1KMT2AKLKB1KLK1 | |
| SCHEMBL11362364 | 0.80 | ALDH1A1 (0.53) | ALDH1A1L3MBTL1KMT2AGAAMEN1 | |
| SCHEMBL6052401 | 0.79 | ALDH1A1 (0.56) | ALDH1A1L3MBTL1KMT2AKLKB1KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250257061-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS | STEMSYNERGY THERAPEUTICS INC (US) | 2025-08-14 | — | — | US | disclosed |
| US-20090048258-A1 | Amide Compound | TAKEDA, PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-19 | — | — | US | disclosed |
| US-20090048258-A1 | Amide Compound | TAKEDA, PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-19 | — | — | US | disclosed |
| US-20090048258-A1 | Amide Compound | TAKEDA, PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-19 | — | — | US | disclosed |
| EP-1845081-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-10-17 | — | — | EP | disclosed |
| EP-0772597-B1 | 3,4-SUBSTITUTED PYRAZOLES FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2001-12-12 | — | — | EP | disclosed |
| EP-1127878-A1 | 3,4 - substituted pyrazoles for the treatment of inflammation | G.D. SEARLE & CO. (US) | 2001-08-29 | — | — | EP | disclosed |
| US-6028072-A | 3,4-substituted pyrazoles for the treatment of inflammation | G. D. SEARLE & CO. (US) | 2000-02-22 | — | — | US | disclosed |
| EP-0772597-A1 | 3,4-SUBSTITUTED PYRAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-05-14 | — | — | EP | disclosed |
| US-5580985-A | ANTIARTHRITIC AGENT; SIDE EFFECT REDUCTION | G. D. SEARLE & CO. (US) | 1996-12-03 | — | — | US | disclosed |
| WO-1996003385-A1 | 3,4-SUBSTITUTED PYRAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250257061-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS | WNT1, WNT3A, CTNNB1 | ALDH1A1 825/4885L3MBTL1 2583/4885KMT2A 3200/4885 |
| US-20090048258-A1 | Amide Compound | DLAT, DGAT1, DGAT2 | ALDH1A1 435/4885L3MBTL1 2152/4885KMT2A 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.